Magda Nakou

Summary

Publications

  1. ncbi Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response
    Magda Nakou
    Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Medical School, Voutes, Heraklion, Greece
    Arthritis Res Ther 11:R131. 2009
  2. ncbi Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus
    George K Bertsias
    University of Crete Medical School, Heraklion, Crete, Greece
    Arthritis Rheum 60:207-18. 2009

Collaborators

  • Helen A Papadaki
  • George K Bertsias
  • Christianna Choulaki
  • Eva Papadimitraki
  • Maria Tzardi
  • Amalia Raptopoulou
  • Prodromos Sidiropoulos
  • Clio Mamalaki
  • Dimitris Kardassis
  • Herakles Kritikos
  • Dimitrios T Boumpas
  • George Goulielmos

Detail Information

Publications2

  1. ncbi Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response
    Magda Nakou
    Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Medical School, Voutes, Heraklion, Greece
    Arthritis Res Ther 11:R131. 2009
    ..We investigated the effect of rituximab (anti-CD20 mAb) in peripheral blood (PB) and BM B-cell and T-cell populations in active rheumatoid arthritis (RA) patients...
  2. ncbi Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus
    George K Bertsias
    University of Crete Medical School, Heraklion, Crete, Greece
    Arthritis Rheum 60:207-18. 2009
    ..We undertook this study to determine the expression and function of PD-1 in SLE patients...